About 22 results found for searched term "JAK3-IN-7" (0.134 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M49594 | JAK3-IN-7 | JAK |
| JAK3-IN-7 is a potent and selective JAK3 inhibitor extracted from patent WO2011013785A1, has an IC50 of <0.01 μM. | ||
| M3141 | ZM 39923 hydrochloride | JAK |
| ZM 39923 is an JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to be sensitive to transglutaminase. | ||
| M3535 | Gandotinib | JAK |
| LY2784544 | ||
| Gandotinib (LY2784544) is a potent JAK2 inhibitor with IC50 of 3 nM, effective in JAK2V617F, 8- and 20-fold selective versus JAK1 and JAK3. | ||
| M3735 | JAK2 Inhibitor V | JAK |
| NSC 42834, Z3 | ||
| JAK2 Inhibitor V, Z3 is a novel specific inhibitor of Jak2 which inhibits Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner but was not cytotoxic to cells at concentrations that inhibited kinase activity. | ||
| M11227 | FM-479 | JAK |
| Fm-479 was a negative control of FM-381 and showed no activity against JAK3 or other kinases. Fm-381 is a potent covalent reversible inhibitor of JAK3 targeting unique Cys909. For JAK3, FM-381 was 410, 2700 and 3600 times more selective than JAK1, JAK2 and TYK2 with IC50 of 127 pM. | ||
| M4288 | Atractylenolide I | TLR |
| Atractylenolide I is a sesquiterpene obtained from the roots of Atractylenolide. Atractylenolide I has neuroprotective, anti-allergic, anti-inflammatory and anticancer activities. Atractylenolide I is an antagonist of TLR4 and can also reduce the phosphorylation of JAK2 and STAT3 in A375 cells. | ||
| M4980 | Decernotinib | JAK |
| VX-509; VRT-831509 | ||
| Decernotinib is a potent and selective Janus kinase 3 (JAK3) inhibitor with Ki of 2.5 nM; IC50 is 50-170 nM in cellular assays. | ||
| M6297 | Upadacitinib | JAK |
| ABT-494 | ||
| Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research. | ||
| M9627 | JAK3-IN-6 (Compound 2) | JAK |
| JAK3-IN-2 | ||
| JAK3-IN-6 (Compound 2) CAS#: 1443235-95-7 is a potent and highly selective JAK3 inhibitor, with an IC50 of 0.15 nM. | ||
| M10437 | PF-06700841 | JAK |
| PF-06700841 free base; Brepocitinib | ||
| PF-06700841 is a first-in-class oral dual inhibitor of JAK1 and TYK2 with IC50 values of 17 nM and 23 nM, respectively.PF-06700841 also inhibits JAK2 and JAK3 with IC50s of 77 nM and 6.49 μM, respectively. | ||
| M10698 | FM-381 | JAK |
| FM-381 is a potent, covalent, reversible JAK3 inhibitor that targets the Cys909 site. FM-381 for JAK3 IC50 The value is 127 pM, which is 410, 2700, and 3600 times more selective than JAK1, JAK2, and TYK2, respectively. | ||
| M28334 | JAK-IN-3 | JAK |
| JAK-IN-3 (compound 22) is a potent JAK inhibitor, with IC50 values of 3 nM, 5 nM, 34 nM and 70 nM for JAK3, JAK1, TYK2 and JAK2, respectively. | ||
| M31205 | G5-7 | JAK |
| G5-7 is an orally active and allosteric JAK2 inhibitor, selectively inhibits JAK2 mediated phosphorylation and activation of EGFR (Tyr1068) and STAT3 by binding to JAK2. G5-7 induces cell cycle arrest, apoptosis and possesses antiangiogenic effect. G5-7 has the potential for glioma study. | ||
| M49572 | JAK1/TYK2-IN-3 | JAK |
| JAK1/TYK2-IN-3 is a potent, selective and orally active dual TYK2/JAK1 inhibitor with IC50 values of 6 and 37 nM, respectively. | ||
| M49579 | JAK-2/3-IN-1 | JAK |
| JAK-2/3-IN-1 is a potent JAK-2 and JAK-3 inhibitor extracted from patent US8163732B2, compound 46, has Kis of <250 nM for both isoforms. | ||
| M49581 | JAK2/FLT3-IN-1 | JAK |
| JAK2/FLT3-IN-1 is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. | ||
| M49583 | JAK2-IN-4 | JAK |
| JAK2-IN-4 is a selective JAK2/JAK3 inhibitor, with IC50 values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively. | ||
| M49592 | JAK3-IN-11 | JAK |
| JAK3-IN-11 , a potent, noncytotoxic, irreversible, orally active JAK3 inhibitor with IC50 value of 1.7 nM, has excellent selectivity (>588-fold compared to other JAK isoforms), covalently bind to the ATP-binding pocket in JAK3. | ||
| M49595 | JAK3-IN-9 | JAK |
| JAK3-IN-9 is an orally active JAK3 inhibitor with IC50 value of 1.7 nM. | ||
| M49603 | JAK-IN-21 | JAK |
| JAK-IN-21 is a selective and potent JAK inhibitor with IC50s of 1.73, 2.04, 109 and 62.9 nM against JAK1, JAK2, J2V617F and TYK2, respectively. | ||
| M49635 | ZM39923 | JAK |
| ZM39923 is a JAK3 inhibitor, with a pIC50 of 7.1; ZM39923 also potently inhibits tissue transglutaminase (TGM2) with an IC50 of 10 nM. | ||
| M49651 | JAK2/FLT3-IN-1 TFA | JAK |
| JAK2/FLT3-IN-1 (TFA) is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
